Objective To evaluate the efficacy of Vonoprazan to treat gastroesophageal reflux disease (GERD).
Methods The randomized controlled trials of Vonoprazan in the treatment of gastroesophageal reflux disease were retrieved in the Cochrane Library, PubMed, EMBASE, China Biomedical Literature Database (CBM), China National Knowledge Infrastructure (CNKI), and WanFang Data. The key words included "Vonoprazan", "TAK-438","gastroesophageal reflux", "GERD", "erosive esophagitis", "non-erosive reflux disease", "reflux esophagitis". Data extraction and the evaluation of the inclusive literature quality were conducted independently by 2 reviewers . Meta-analysis was carried out by the RevMan software5.4.
Results we obtained 108 publications through searching the literature dababase and cited references. And after removal of the study with the exclusive criteria, 10 remained. In the main analysis, there was no significant difference (P>0.05) in the efficacy between Vonoprazan and the control group (RR=1.07, 95%CI: 1.01-1.13). In the baseline analysis, the subgroup analysis showed significant effective therapy in the severe esophagitis (LA grade C/D) compared with the proton pump inhibitors (PPIs) (RR=1.14, 95%CI: 1.06-1.22; P<0.05). however, the analysis results indicated that no significant difference cound be seen in different doses of vonoprazan as a therapy in GERD. (P>0.05) (RR=1.36, 95% CI: 1.03-1.79).
Conclusion Vonoprazan is more effective than PPIs in the treatment of GERD, especially in severe esophagitis (LA grade C/D). The safety is similar to PPIs. And 10mg, 20mg, or 40 mg vonoprazan present with the same efficacy in the treatment of GERD.